Literature DB >> 34718172

A Gap in Care Leads to Progression of Fibrosis in Eosinophilic Esophagitis Patients.

Nicole C Chang1, Kisan P Thakkar1, Corey J Ketchem1, Swathi Eluri1, Craig C Reed1, Evan S Dellon2.   

Abstract

BACKGROUND & AIMS: There are few data assessing disease progression in eosinophilic esophagitis (EoE) after diagnosis. We aimed to determine outcomes and assess for progression of fibrosis in patients with EoE with a gap in their regular care.
METHODS: In this retrospective cohort study of newly diagnosed patients with EoE, a "gap" in care was defined as ≥2 years without medical contact for EoE. For inclusion, a gap in care and both pre- and post-gap endoscopies were required. Patients with and without a gap were compared. Data were also compared in gap patients before the gap and after EoE care resumed, and progression of fibrosis and predictors were assessed.
RESULTS: Of 701 patients with EoE, 95 (14%) had a gap in care (mean time without care, 4.8 ± 2.3 years). Post-gap, 12% presented with food impaction requiring emergency evaluation. Compared with pre-gap, patients post-gap had higher endoscopic severity (2.4 vs 1.5; P < .001) and smaller esophageal diameters (11.0 vs 12.7 mm; P = .04). Strictures were more prevalent with longer gap time (P < .05 for trend). Each additional year of gap time increased odds of stricture by 26%, even after accounting for pre-gap dilation. Additionally, of 67 patients without pre-gap fibrosis, 25 (37%) had at least one fibrotic feature (stricture, narrowing, or requiring dilation) post-gap.
CONCLUSIONS: A gap in care of ≥2 years in patients with EoE was associated with signs of increased disease activity, and progression to fibrostenosis was noted, particularly with longer gaps in care. Because EoE can progress to fibrosis even after diagnosis, regular care in patients with EoE is required, perhaps at intervals <2 years.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dilation; Eosinophilic Esophagitis; Fibrosis; Natural History; Outcomes; Stricture

Mesh:

Year:  2021        PMID: 34718172      PMCID: PMC9043028          DOI: 10.1016/j.cgh.2021.10.028

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  30 in total

1.  Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.

Authors:  Alex Straumann; Sebastien Conus; Lukas Degen; Cornelia Frei; Christian Bussmann; Christoph Beglinger; Alain Schoepfer; Hans-Uwe Simon
Journal:  Clin Gastroenterol Hepatol       Date:  2011-01-28       Impact factor: 11.382

2.  Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype.

Authors:  Thomas M Runge; Swathi Eluri; Cary C Cotton; Caitlin M Burk; John T Woosley; Nicholas J Shaheen; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

Review 3.  Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.

Authors:  Ikuo Hirano; Seema S Aceves
Journal:  Gastroenterol Clin North Am       Date:  2014-04-16       Impact factor: 3.806

4.  Clinical tolerance in eosinophilic esophagitis.

Authors:  Melanie A Ruffner; Terri F Brown-Whitehorn; Ritu Verma; Antonella Cianferoni; Laura Gober; Michele Shuker; Amanda B Muir; Chris A Liacouras; Jonathan M Spergel
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-12

5.  Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.

Authors:  Alex Straumann; Alfredo J Lucendo; Stephan Miehlke; Michael Vieth; Christoph Schlag; Luc Biedermann; Cecilio Santander Vaquero; Constanza Ciriza de Los Rios; Christoph Schmoecker; Ahmed Madisch; Petr Hruz; Jamal Hayat; Ulrike von Arnim; Albert Jan Bredenoord; Stefan Schubert; Ralph Mueller; Roland Greinwald; Alain Schoepfer; Stephen Attwood
Journal:  Gastroenterology       Date:  2020-07-25       Impact factor: 22.682

Review 6.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

7.  Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients.

Authors:  Thomas Greuter; Ekaterina Safroneeva; Christian Bussmann; Luc Biedermann; Stephan R Vavricka; David A Katzka; Alain M Schoepfer; Alex Straumann
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-11       Impact factor: 11.382

8.  The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood.

Authors:  P Menard-Katcher; K L Marks; C A Liacouras; J M Spergel; Y-X Yang; G W Falk
Journal:  Aliment Pharmacol Ther       Date:  2012-11-05       Impact factor: 8.171

9.  Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation.

Authors:  Craig C Reed; S Ryanne Corder; Erin Kim; Emily Sanders; Manaswita Tappata; Swathi Eluri; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

10.  Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis.

Authors:  Dustin A Carlson; Ikuo Hirano; Angelika Zalewski; Nirmala Gonsalves; Zhiyue Lin; John E Pandolfino
Journal:  Clin Transl Gastroenterol       Date:  2017-10-05       Impact factor: 4.488

View more
  3 in total

1.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2022-05-20       Impact factor: 14.290

2.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  Gastroenterology       Date:  2022-05-20       Impact factor: 33.883

3.  Worsened Fibrostenotic Outcomes in Eosinophilic Esophagitis Patients Due to COVID-19-Related Endoscopy Cancellations.

Authors:  Adolfo A Ocampo; Evan S Dellon
Journal:  Dig Dis Sci       Date:  2022-07-05       Impact factor: 3.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.